Dwayne 'The Rock' Johnson TRT: How His Approach Compares to Similar Public Figures

What Dwayne Johnson Has Actually Said Publicly

Johnson's public record on hormone use is narrower than media coverage suggests. He has confirmed one thing clearly, and everything beyond that is reported or inferred.

In a 1999 Rolling Stone profile, Johnson told the magazine he experimented with anabolic steroids at age 18 while at the University of Miami. He described the experience as a youthful mistake and said he stopped. That admission is the only on-the-record disclosure Johnson has made about any hormone use. [1]

The Reported TRT Claims

Multiple fitness and entertainment journalists have reported that Johnson uses TRT as part of his current health regimen. None of those reports cite a direct quote from Johnson confirming a current TRT protocol, a prescribing physician, or a specific compound and dose. Characterizing those reports as confirmed fact would be inaccurate.

What is reasonable to note clinically: Johnson is 52 years old, maintains an extreme training schedule (he has described six-day-per-week sessions lasting 60 to 90 minutes), and carries substantially more lean mass than most men his age. Each of those factors is consistent with medically supervised hormone optimization, but none of them proves it.

Human Growth Hormone Speculation

HGH (recombinant human growth hormone, somatropin) is frequently mentioned alongside Johnson's name online. The FDA has approved somatropin for adult growth hormone deficiency, short bowel syndrome, and HIV-associated wasting, but not for anti-aging or body composition enhancement in otherwise healthy adults. [2] Using somatropin for those unapproved purposes carries regulatory and clinical risk. No credible source has published a confirmed account of Johnson using HGH.

How TRT Is Defined Clinically and Why It Matters for This Discussion

TRT is not a lifestyle supplement. It is a medical intervention for biochemically confirmed hypogonadism.

The Endocrine Society's 2018 Clinical Practice Guideline states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations." [3] Two fasting, morning total testosterone measurements below 300 ng/dL, obtained on separate days, are required before initiating therapy under that guideline.

Symptoms That Warrant Testing

Common symptoms of hypogonadism in men over 40 include reduced libido, fatigue, depressed mood, decreased bone density, and loss of lean mass. A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (pooling data from 40 studies, N=36,369) found that serum testosterone declines roughly 1 to 2 percent per year after age 30 in healthy men. [4] By age 52, a man who started at 600 ng/dL might realistically measure in the 400s, still within normal range, but lower than his peak.

Approved Delivery Forms

The FDA has approved multiple testosterone delivery systems: intramuscular injection (testosterone cypionate, testosterone enanthate), transdermal gel (AndroGel, Testim, Fortesta), transdermal patch (Androderm), buccal tablet (Striant), subcutaneous pellet (Testopel), and intranasal gel (Natesto). [2] Weekly or biweekly testosterone cypionate 100 to 200 mg IM is among the most common protocols in U.S. Men's health clinics, though dosing is individualized to achieve a target trough total testosterone of 400 to 700 ng/dL.

Comparing Johnson to Similar High-Profile Men in Their 50s

Several public figures in the same demographic bracket, men aged 50 to 60 with significant physical presence or public health brands, have discussed testosterone therapy more openly than Johnson has.

Joe Rogan

Joe Rogan (born August 11, 1967) has discussed TRT, HGH, and testosterone cypionate use on his podcast, the Joe Rogan Experience, across multiple episodes. He has described working with an anti-aging physician and has named testosterone as part of his protocol. Rogan's openness is unusual among celebrities; he has explicitly acknowledged that he uses pharmacological support and chooses not to compete in any tested athletic organization.

Clinically, Rogan's self-described approach, which reportedly includes testosterone, HGH, and other compounds, goes well beyond what the Endocrine Society considers standard replacement therapy. His self-reported stack is closer to what the sports medicine literature calls "supraphysiologic" dosing, meaning doses designed to push testosterone above the normal male reference range of roughly 270 to 1,070 ng/dL. [5]

Mark Wahlberg

Mark Wahlberg (born June 5, 1971) has spoken about extreme training regimens and a 4 a.m. Workout schedule. He has not publicly confirmed TRT use, though he has mentioned working with physicians to optimize recovery. At 53, Wahlberg occupies a similar demographic bracket to Johnson. His situation is inferential only.

Vin Diesel

Vin Diesel (born July 18, 1967) is 57 and has been the subject of similar speculation. No credible primary source confirms a TRT protocol for Diesel specifically.

The Pattern Across This Cohort

What these men share is more clinically interesting than any specific drug claim. All are over 50, maintain high physical output professionally, have significant financial and reputational incentives to maintain their physiques, and have access to concierge-level medical care that most men do not. That combination, regardless of any one individual's specific protocol, describes a population that is statistically more likely to be screened for hypogonadism and more likely to receive treatment when it is found.

A 2013 JAMA Internal Medicine study analyzing pharmacy data from 1.1 million commercially insured men found that testosterone therapy initiations increased from 0.81 percent of men in 2001 to 2.91 percent in 2011, with the sharpest growth in men aged 40 to 64. [6] High-income men with direct-to-physician access likely saw even higher rates.

What the Evidence Actually Shows About TRT Outcomes in Men Over 50

The clinical picture for TRT in this age group became considerably clearer after two major trials published results in the past few years.

The TRAVERSE Trial (2023)

TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE) enrolled 5,204 men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease. [7] Published in the New England Journal of Medicine in 2023, the trial found that testosterone replacement (1.62% gel titrated to achieve testosterone levels of 350 to 750 ng/dL) did not significantly increase major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17; P<0.001 for non-inferiority). [7]

The same trial did find a statistically higher rate of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (2.3% vs. 1.5%) in the testosterone arm. These signals are clinically relevant and should be part of any informed consent conversation.

The TTrials (Testosterone Trials)

The seven coordinated Testosterone Trials, funded by the NIH and reported in JAMA and the New England Journal of Medicine between 2016 and 2018, enrolled 790 men aged 65 and older with a total testosterone below 275 ng/dL. [8] The Sexual Function Trial showed improvement in sexual desire and erectile function. The Physical Function Trial showed a modest but statistically significant improvement in walking distance. The Bone Trial showed increased volumetric bone density. Cognitive outcomes were neutral.

For a 52-year-old man like Johnson, the TTrials are less directly applicable, since the median age was 72. Still, the mechanistic findings, including improved bone density and modest physical function gains, likely extend to younger hypogonadal men.

Hematologic Risk: Erythrocytosis

One of the most consistent adverse effects of TRT across studies is erythrocytosis, defined as a hematocrit above 54 percent. The Endocrine Society recommends withholding or reducing TRT doses when hematocrit exceeds 54 percent because of the associated risk of venous thromboembolism. [3] Any man on TRT should have a complete blood count at 3 months, then annually.

The Anabolic Steroid Question: Past Use and Long-Term Physiological Effects

Johnson's confirmed teenage steroid use is medically relevant beyond the headline.

Anabolic androgenic steroid (AAS) use during adolescence, when the hypothalamic-pituitary-gonadal (HPG) axis is still maturing, may produce lasting suppression of endogenous testosterone production. A 2019 paper in the Journal of Clinical Endocrinology and Metabolism found that former AAS users had significantly lower serum testosterone (mean 12.4 nmol/L) compared to age-matched controls (mean 17.4 nmol/L) even years after cessation, and a higher prevalence of hypogonadism requiring treatment. [9]

If Johnson's adolescent steroid use contributed to blunted HPG axis function, then a TRT diagnosis in his adult years would carry a plausible biochemical rationale. This is inference, not confirmed fact, and is labeled as such here.

A Clinical Decision Framework for Athletes With Prior AAS History

Men who used AAS during adolescence or early adulthood and now present with symptoms of hypogonadism should be evaluated with the following protocol, based on current Endocrine Society and American Urological Association guidance:

1. Two fasting, morning total testosterone measurements taken at least one week apart.
2. Free testosterone (calculated or equilibrium dialysis), LH, FSH, and SHBG to characterize whether the deficiency is primary (testicular) or secondary (pituitary/hypothalamic).
3. Prolactin to exclude pituitary adenoma.
4. CBC, PSA, lipid panel, and blood pressure prior to initiation.
5. Discussion of fertility implications: exogenous testosterone suppresses spermatogenesis. Men who desire future fertility should consider clomiphene citrate or hCG-based protocols instead of direct testosterone replacement.

This framework applies equally to any man with prior AAS exposure, regardless of public profile.

Realistic Expectations: What TRT Can and Cannot Do

Johnson's physique, which includes an estimated 260-plus pounds of lean mass on a 6-foot-5-inch frame, is not achievable through TRT alone. This point is worth being direct about.

Medically supervised TRT in hypogonadal men produces modest, measurable improvements. A 2016 Cochrane systematic review of 58 randomized controlled trials found that TRT produced a mean increase in lean body mass of approximately 1.6 kg and a mean decrease in fat mass of approximately 1.6 kg versus placebo. [10] That is a clinically meaningful but modest change, not the body composition of a professional athlete.

What Else Matters

Caloric intake, protein synthesis driven by years of progressive resistance training, sleep quality, and genetics all account for a much larger portion of body composition than TRT alone can explain. Johnson has been public about consuming roughly 5,000 to 6,000 calories per day during building phases and training twice daily at peak production demand. That level of nutritional and mechanical stimulus produces adaptations that exist largely independent of testosterone levels, as long as testosterone is within a normal range.

The Supraphysiologic Distinction

TRT targets a trough testosterone within the normal male reference range, typically 400 to 700 ng/dL at trough for most U.S. Clinics. Anabolic steroid protocols used in competitive bodybuilding may push testosterone levels to 1,500 to 4,000 ng/dL or higher, alongside other compounds such as nandrolone, stanozolol, or trenbolone. The physiological and risk profile of those protocols is entirely different from medically supervised TRT, and conflating the two is a clinical error.

The American Urological Association's 2018 guidelines state: "Testosterone therapy is not recommended for men who are interested primarily in improving athletic performance or physical appearance." [11]

Privacy, Public Disclosure, and Patient Autonomy

Johnson, like any patient, has no legal or ethical obligation to disclose his medical treatments publicly. The speculation that surrounds him, and similar figures, reflects public curiosity rather than any genuine clinical transparency norm. Physicians are bound by HIPAA and professional ethics; patients are not bound to disclose anything.

What does matter publicly is accuracy. When media conflates confirmed teenage steroid use with assumed adult TRT, or presents anecdotal performance claims as evidence of specific drug protocols, it distorts both the public's understanding of TRT and the legitimate clinical use of the therapy.

A 2022 survey published in Andrology found that 40 percent of men seeking TRT evaluations cited celebrity or social media influence as a contributing factor in their decision to seek testing. [12] Accurate, nuanced coverage of what public figures have and have not confirmed is part of responsible health journalism.

When to Seek Evaluation: Signs That TRT May Be Medically Appropriate

If you are a man over 40 experiencing persistent fatigue, low libido, mood changes, decreased muscle mass despite consistent training, or bone density loss, a testosterone panel is a reasonable first step. The test itself costs roughly $30 to $60 through most commercial labs and is covered by most insurance plans when ordered with a diagnosis code for suspected hypogonadism (ICD-10 E29.1).

A single low result is not sufficient for diagnosis. Two morning measurements, ideally drawn between 7 a.m. And 10 a.m. When testosterone peaks, both below 300 ng/dL, are required under Endocrine Society criteria before any therapeutic conversation begins. [3]

Men with a history of prostate cancer, a hematocrit above 50 percent, untreated sleep apnea, severe lower urinary tract symptoms, or a recent cardiovascular event should not initiate TRT until those conditions are addressed or cleared by the appropriate specialist.